[Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
Schlenker
Boris
B
Urologische Klinik und Poliklinik, Klinikum der Universität München-Grosshadern, München. boris.schlenker@med.uni-muenchen.de
Beer
André-Michael
AM
Gratzke
Christian
C
Tilki
Derya
D
Seitz
Michael
M
Stief
Christian G
CG
Reich
Oliver
O
D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000465:Algorithms; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016896:Treatment Outcome; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy*
D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010936:Plant Extracts